XML 176 R103.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and intangible assets (Details 4) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Intangible Assets other than Goodwill      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge $ (1,326.0) $ (403.0) $ (914.0)
Acquired research and development [member]      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (917.0) (350.0)  
Technologies      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (15.0) (17.0)  
Currently marketed products      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (322.0) (1.0)  
Other intangible assets      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (72.0) (35.0)  
Innovative Medicines | Votrient [member] | Currently marketed products      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (900.0) (1,300.0)  
Operating segments [member] | Innovative Medicines | Intangible Assets other than Goodwill      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (1,299.0) (367.0) (768.0)
Operating segments [member] | Sandoz | Intangible Assets other than Goodwill      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (25.0) (28.0) (141.0)
Operating segments [member] | Corporate | Intangible Assets other than Goodwill      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge (2.0) (8.0) (5.0)
Accumulated depreciation, amortisation and impairment | Innovative Medicines | Acquired research and development [member]      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge $ (0.6) $ (0.2) (0.5)
Accumulated depreciation, amortisation and impairment | Innovative Medicines | Votrient [member] | Acquired research and development [member]      
Disclosure of detailed information about intangible assets [line items]      
Impairment charge     $ (0.2)